Reprogramming of bone marrow myeloid progenitor cells in patients with severe coronary artery disease.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 33168134.
- Also identified by DOI 10.7554/eLife.60939 and PMC identifier 7665893.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Atherosclerosis is the major cause of cardiovascular disease (CVD). Monocyte-derived macrophages are the most abundant immune cells in atherosclerotic plaques. In patients with atherosclerotic CVD, leukocytes have a hyperinflammatory phenotype. We hypothesize that immune cell reprogramming in these patients occurs at the level of myeloid progenitors. We included 13 patients with coronary artery disease due to severe atherosclerosis and 13 subjects without atherosclerosis in an exploratory study. Cytokine production capacity after <i>ex vivo</i> stimulation of peripheral blood mononuclear cells (MNCs) and bone marrow MNCs was higher in patients with atherosclerosis. In BM-MNCs this was associated with increased glycolysis and oxidative phosphorylation. The BM composition was skewed towards myelopoiesis and transcriptome analysis of HSC/GMP cell populations revealed enrichment of neutrophil- and monocyte-related pathways. These results show that in patients with atherosclerosis, activation of innate immune cells occurs at the level of myeloid progenitors, which adds exciting opportunities for novel treatment strategies.
Medical subject headings
- Atherosclerosis
- Bone Marrow Cells
- Cellular Reprogramming Techniques
- Coronary Artery Disease
- Leukocytes, Mononuclear
- Myeloid Progenitor Cells